- Details
- Despite the fact that most patients do well with a radical cystectomy, the procedure is physiologically challenging and is associated with real morbidity, including hospitalizations, risk of re-operation, long-term sequelae and post-operative mortality. Jason Efstathiou, MD discusses the progress in trimodality therapy with the combination of surgery, chemotherapy, and radiation. Trimodality thera...
|
- Details
- Andrea Necchi and Alicia Morgans discuss the evolution of neoadjuvant treatment for muscle-invasive bladder cancer (MIBC) including the role of immunotherapy and chemotherapy prior to radical surgery. They discuss the PURE-01study which included all-comers regardless of cisplatin eligibility. The early data from PURE-01 with neoadjuvant pembrolizumab demonstrated a 42% pathological complete respon...
|
- Details
- Scott Tagawa discusses his recent research on the use of antibody-drug conjugate (ADC) sacituzumab govitecan in advanced metastatic urothelial carcinoma. The primary endpoint of the study was the objective response rate and the results of the Phase 2 subset were presented at ASCO GU 2019. The responses were seen with reasonable drug tolerance, a manageable and predictable safety profile, and a rel...
|
- Details
- Josh Meeks reviews the SWOG 1806 study protocol with Alicia Morgans. T he SWOG 1806 study , Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer is expected to begin enrollment in May 2019. This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle...
|
- Details
- Matthew Galsky and Alicia Morgans share in a discussion on combination and maintenance strategies for muscle-invasive and metastatic bladder cancer and a number of reasons for combining immunotherapy with immune checkpoint blockade. These reasons include the concept of immunogenic cell death, depletion of suppressive immune cell subsets and independent drug action. Biographies: Matthew Galsky, MD,...
|
- Details
- Alicia Morgans interviews Andrea Apolo who details the trial design and current status of the Phase III adjuvant AMBASSADOR trial for patients with high-risk muscle-invasive bladder cancer (MIBC) and the need to develop additional treatment options for patients who are resistant to chemotherapy and develop recurrent disease. The AMBASSADOR trial aims to answer the question if there is a benefit to...
|
- Details
- (Length of Discussion: 12 min) A conversation between Petros Grivas and Alicia Morgans where they discuss the trials in the neoadjuvant, adjuvant and perioperative setting in advanced bladder cancer from ESMO 2018. They talk about the biology of the disease and considerations of available therapies, single vs combination, and for chemotherapy ineligible, as well as patients who opt out of chemothe...
|
- Details
- (Length of interview: 17 min) Cora Sternberg and Alicia Morgans provide a review of immunotherapy advances in both renal cell and bladder cancer. They review past and current trials providing insights into potential clinical and treatment applications. Biographies: Cora Sternberg MD, FACP Clinical Director of the Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, Former Chi...
|
- Details
- (Length of Discussion: 9 min) Evan Yu and Alicia Morgans have a diverse conversation highlighting the advances in the field of bladder cancer beyond IO and Checkpoint inhibition. They introduce a variety of therapy options being studied such as FGFR inhibition, antibody-drug conjugates, HER-2 and DNA repair. Biographies: Evan Yu, MD Alicia Morgans, MD Referenced in this discussion: Targeted Therap...
|
- Details
- (Length of Discussion: 21 min) Petros Grivas and Pedro Barata discuss how a recent study they performed applies to the field of metastatic urothelial cancer regarding the use of checkpoint inhibitors in a patient population outside the context of the clinical trial and the main objectives, results, and conclusion of that study as well as implications for the field. Biographies: Pedro Barata, MD, M...
|
